FLNA logo

FILANA THERAPEUTICS INC

FLNANASDAQ
πŸ† #4376 by market capEarnings Mar 2US Equity
$0.64β–² $0.08 (+14.52%)
Market closed Β· at close
πŸ””
Track FLNA
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 14.5%
7dβ–² 50.6%
14dβ–² 45.1%
30dβ–² 0.0%
ytdβ–Ό 67.4%
1yβ–Ό 77.7%
🏦Market Cap
$31M
Small Cap
πŸ“ˆRevenue Growth (YoY)
0.0%
Slowing
πŸ“ŠGross Margin
0.0%
Thin
πŸ’΅FCF Margin
0.0%
Thin
βš–οΈP/S Ratio
0.0x
Cheap
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$0.59 – $0.65
52-Week Range
$0.39 – $3.45
Volume (shares)
1,332,414
Avg Volume (shares)
β€”
Shares Outstanding
48.3M
Next Earnings
2027-03-02

Fundamentals Snapshot

Annual Revenue
β€”
Last Q Revenue
β€”
P/E Ratio
-0.7
P/S Ratio
0.0x
EPS (TTM)
$-0.87
Dividend Yield
0.00%
Dilution (1yr)
βˆ’99.0%
FLNA logo

FILANA THERAPEUTICS INC

FLNA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$95Mβ–Ό βˆ’32.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$33Mβ–Ό βˆ’71.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
48.3Mβ–Ό βˆ’99.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$96Mβ–Ό βˆ’$33M YoY
StockOtter Β· stockotter.space

About FILANA THERAPEUTICS INC

Filana Therapeutics, Inc. is a company dedicated to pioneering new pharmaceutical products and diagnostic technologies. A key area of its research is focused on creating potential treatments for Alzheimer's disease, including the investigational compounds PTI-125 and PTI-125Dx. Established by Remi Barbier in May 1998, the firm maintains its principal office in Austin, Texas.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

GlobeNewsWireΒ·11d ago

Filana Therapeutics Names Biopharma Executive Jill M. Quigley to Board

AUSTIN, Texas, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA), a biotechnology company focused on developing therapies for Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced th

GlobeNewsWireΒ·25d ago

Filana Therapeutics Announces Publication in Cells of Promising Preclinical Findings for Simufilam in TSC2-Deficient Cells

Findings provide new insight into simufilam's effects on cellular stress responses and mitochondrial function New research demonstrates a 37% reduction in elevated ATF4, consistent with attenuation of the ATF4-associated

GlobeNewsWireΒ·Oct 9

Filana Therapeutics to Participate in the 2026 Maxim Growth Summit

Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for the treatment of Tuberous Sclerosis Complex (TSC)-related epilepsy, to

BenzingaΒ·Sep 22

Positive FDA Decision Propels Rebranded Filana Therapeutics Epilepsy Research Forward

The U.S. Food and Drug Administration (FDA) on Tuesday removed a clinical hold on the investigational new drug application for Filana Therapeutics, Inc. (NASDAQ:FLNA).

GlobeNewsWireΒ·Sep 22

Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy

Patient screening for the Phase 2a study is expected to begin by the first quarter of 2027 Filana has engaged a leading clinical research organization, has identified clinical trial sites, and is recruiting potential inv